Lakewood-Amedex Biotherapeutics Surges as Fresh Nu-3 Data Draws Attention to Its Antibiotic-Resistance Program

By: Quiver PriceTracker

Posted: an hour ago / July 22, 2026 2:52 p.m. UTC

LABT

Lakewood-Amedex Biotherapeutics (LABT) is up 105.9% today. Here is some analysis on what might have caused this price movement.

Analysis: The sharp move appears tied primarily to a July 22 company announcement highlighting new resistance data for Nu-3, its lead antimicrobial candidate for infected diabetic foot ulcers. The rally may have been amplified by the stock’s very small post-split share count and its recent Nasdaq listing, which can make biotech shares especially volatile when fresh development news hits.

Details:

The company said Nu-3 showed resistance data that supports its broader effort to develop therapies aimed at drug-resistant infections.

A company update from July 15 also outlined preclinical safety data that supported dose selection for an upcoming Phase 2a trial of Nu-3 gel, reinforcing the near-term clinical story.

A July 15 investor presentation described Nu-3 as Phase 2-ready and pointed to planned milestones including trial commencement and a first-patient visit in the third quarter of 2026.

A June 2026 reverse stock split reduced outstanding common shares to roughly 1.75 million, which could help explain why heavy trading volume translated into an outsized percentage gain.

Sources:

Lakewood-Amedex Biotherapeutics, SEC, Nasdaq

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$LABT Hedge Fund Activity

We have seen 1 institutional investors add shares of $LABT stock to their portfolio, and 0 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

BLUE TRUST, INC. added 11 shares (+inf%) to their portfolio in Q2 2026, for an estimated $34

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.